Skip to main content
Clinical Trials/NCT04735874
NCT04735874
Completed
Not Applicable

Vascular Health and Risk Factors in Children With Down Syndrome

University of Utah1 site in 1 country55 target enrollmentFebruary 2, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Down Syndrome
Sponsor
University of Utah
Enrollment
55
Locations
1
Primary Endpoint
The difference in mean pulse wave velocity between children with Down syndrome and published national data in children without Down syndrome at one time point.
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This is a prospective, multicenter, cross-sectional study to evaluate prevalence of vascular risk factors in children with Down Syndrome and to determine the association between vascular disease risk factors and objective markers of early atherosclerosis.

Registry
clinicaltrials.gov
Start Date
February 2, 2021
End Date
June 30, 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Adam Ware

MD, Assistant Professor, Pediatric Cardiology

University of Utah

Eligibility Criteria

Inclusion Criteria

  • All children with Down Syndrome (10.0-18.0 years of age)
  • Children with translocations and mosaicism
  • Children with and without CHD

Exclusion Criteria

  • Patients with a history of hypoplastic arch, coarctation or catheter or surgical based aorta interventions
  • Patients who are currently treated or have been treated with chemotherapy for cancer or a myeloproliferative disorder within 1 year of the study
  • Participants whose parent/legally authorized representative (LAR) perceives the child is not able to cooperate with vascular imaging studies

Outcomes

Primary Outcomes

The difference in mean pulse wave velocity between children with Down syndrome and published national data in children without Down syndrome at one time point.

Time Frame: One day patient visit

Pulse wave velocity (PWV) is a non-invasive imaging measure of arterial stiffness. Pulse wave velocity measures vascular stiffness by evaluating the time for a pressure wave to travel through the aorta. The velocity is determined by the elasticity and geometry of the vessel. PWV will be measured using a SphygmoCor device. With the participant in the supine position and ECG leads attached, the maximal pulsation of the right carotid and right femoral artery will be marked and measured from the suprasternal notch using a tape measure (carotid) and caliper (femoral). A tonometer will record the carotid and femoral impulses. The device calculates PWV as the difference in the carotid-to-distal path length divided by the difference in R-wave-to-waveform times (∆distance/∆time, m/sec). Measurements will be in triplicate and averaged. PWV can be completed in \~30 mins.

Secondary Outcomes

  • Correlation of serologic cardiovascular risk factors include insulin resistance on PWV and CIMT in children with Down syndrome.(One day patient visit)
  • Correlation of waist circumference anthropometric cardiovascular risk factors on PWV and CIMT in children with Down syndrome.(One day patient visit)
  • Correlation of serologic cardiovascular risk factors include lipoprotein on PWV and CIMT in children with Down syndrome.(One day patient visit)
  • The difference in mean carotid intimal medial thickness between children with Down syndrome and published national data in children without Down syndrome measured at 1 time point.(One day patient visit)
  • Correlation of body mass index (BMI) anthropometric cardiovascular risk factors on PWV and CIMT in children with Down syndrome.(One day patient visit)
  • Correlation of serologic cardiovascular risk factors include fasting lipid panel on PWV and CIMT in children with Down syndrome.(One day patient visit)
  • Correlation of clinical cardiovascular risk factors on PWV and CIMT in children with Down syndrome.(One day patient visit)

Study Sites (1)

Loading locations...

Similar Trials